SALINE-WASHED RED BLOOD CELLS (WRC)
CMV-seronegative and frozen-deglycerolized blood, when usedto prevent PTCMV, have disadvantages of increased cost and limited availability. CMV harbored within leukocytes is the presumed source of PTCMV. With the IBM 2991 Blood Cell Processor, we achieved 89% reduction in white blood cells using a protocol of long spins (2.5 to 5 min) and slow superout rate (200 ml/min). The average post-wash count was 1300/cu mm (range 200-3000). Fresh frozen plasma (62 units) and platelets (27 units) weregiven without special preparation. We followed 54 CMV-seronegative neonates who received WRC. Birth weights (BW) were less than 1500 gm in 43%. Infants received 1-36 WRC transfusion (avg 6.0 per patient). These WRC were 51% seropositive. Serology (ELISA) and viral cultures were performed at an average of 89.6 days (range 18-147) following the last transfusion. Six infants developed laboratory evidence of CMV infection. Infections in 5of the infants were asymptomatic (BW 1060 (BW , 1960 (BW , 2180 (BW , 2270 .
One infant (BW 720 gm) died after a very complicated course. Dissemination of CMV was noted at autopsy. Presently available methods of leukocyte depletion are inadequate to prevent PTCMV. Our data suggest that CMV-seronegative and frozen deglycerolized blood are preferable to WRC. However, the lack of symptoms in the infected infants suggests that WRC may offer an advantage over conventional blood products. Two t o three month o l d c o t t o n r a t s , seronegative f o r RSV a n t ibody were imnunized a t weekly i n t e r v a l s w i t h three doses o f i nt r a p e r i t o n e a l l y administered preparation o f f o r m a l i n i n a c t i v a t e d and alum p r e c i p i t a t e d RSV. Other groups o f animals who received r a b b i t serum c o n t a i n i n g h i g h l e v e l s o f RSV antibody o r normal r a b b i t serum (NRS) were included as c o n t r o l s . Following RSV immunization a l l animals developed RSV s p e c i f i c antibody i n serum when t e s t e d a week a f t e r t h e admini s t r a t i o n o f t h e l a s t vaccine dose, and RSV antibody p e r s i s t e d i n t h e c o n t r o l group who received RSV immune serum. A l l animals were challenged i n t r a n a s a l l y w i t h l i v e RSV i n a dose o f 2x105 PFU/animal and s a c r i f i c e d 4 days l a t e r . High l e v e l s o f t h e v i r u s were detected i n nasal t u r b i n a t e s and lungs o f t h e c o n t r o l group which r eceived NRS, and l i t t l e o r no v i r u s was recovered from animals who received immune serum o r i n a c t i v a t e d RSV vaccine. H i s t o l o g i c a l studies d i d n o t reveal any pathology i n t h e lungs o f non-vaccinated c o n t r o l s . S i g n i f i c a n t l y , severe bronchoalveolar pathology was observed i n a l l RSV vaccinated animals a f t e r l i v e v i r u s challenge. These observations a r e i d e n t i c a l t o t h e c l i n i c a l experience w i t h experimental use o f i n a c t i v a t e d RSV vaccine i n i n f a n t s . This model should be a 
CSF
p p l i c a b l e t o e v a l u a t i o n o f p r i o r exposure t o l i v e o r i n a c t i v a t e d antigens, o r systemic versus mucosal priming i n t h e e v o l u t i o n o f v i r a l imunopathology.
Buffalo. D i v i s i o n o f InFectious Diseases and Microbioloav. -" -c h i l d r e n ' s Hospital o f Buffalo. Groups o f two t o three month o l d c o t t o n r a t s seronegative f o r RSV antibody were administered r a b b i t anti-RSV serum w i t h RSV antibody t i t e r o f 1:1024 as determined by n e u t r a l i z a t i o n t e s t o r RSV a n t i body negative normal r a b b i t serum, v i a i n t r a p e r i toneal (IP), subcutaneous (SC) o r i n t r a n a s a l (IN) routes. Twenty-four hours a f t e r t h e a d m i n i s t r a t i o n o f serum, a l l animals were challenged I N w i t h 2x105 PFU o f Long s t r a i n l i v e RSV and s a c r i f i -
ced f o u r days l a t e r . Q u a n t i t a t i o n o f RSV r e p l i c a t i o n i n the lungs and nasal t u r b i n a t e s was performed i n HEp-2 c e l l c u l t u r e s . High l e v e l s o f RSV r e p l i c a t i o n was observed i n t h e lungs (103.5 PFU/gm o f t i s s u e ) and nasal t u r b i n a t e s (102.5 PFU/gm o f t i s s u e ) o f r a t s t h a t received normal r a b b i t serum. However, animals t h a t were t r e a t e d w i t h r a b b i t RSV a n t i body-rich serum e x h i b i t e d 100 t o 1000 f o l d r e d u c t i o n i n t h e t i t e r o f v i r u s recovered. The p r o t e c t i v e e f f e c t observed was more s i g n i f i c a n t i n t h e lungs than i n nasal turbinates, regardless o f t h e r o u t e o f administrat i o n o f immune serum. Furthermore, passive a d m i n i s t r a t i o n o f RSV antibody was associated w i t h a t t e n u a t i o n o f pulmonary histopathology, and no imnune complexes weredemonstrated i n t h e lungs. These r e s u l t s suggest t h a t h i g h l e v e l s o f p a s s i v e l y administered RSV antibody a t the mucosal s i t e o r i n t h e p e r i p h e r a l c i r c u l at i o n may l i m i t t h e r e p l i c a t i o n o f t h e v i r u s i n r e s p i r a t o r y t r a c t and thus modify t h e outcome o f subsequent r e s p i r a t o r y d i sease.
LONGITUDINAL ASSESSMENT OF ANTIBODY RESPONSE OF CHILDREN WITH RENAL DISEASE TO PNEUMOCOCCAL VACCINE Robert P Drucker, Mary V. Moggio, Randall E. Harris, Gerald Schiffman, Catherine M. Wilfert Duke Univ Med Center Dewt. of Pediatrics, Durham. NC ' 56 children, including nkphrotic syndrome (NS) patients, renal transplant (TX) recipients and normals, aged 2 to 15 years; were given a pneumococcal vaccine containing 14 polysaccharide (PS) types. Vaccine A with 5Oug of each PS type was compared to Vaccine B with 25ug of each type. Study divisions were: Group 1)16 NS patients, Vaccine A; Group 2)lONS patients, Vaccine B; Group 3)3 TX patients, A; Group 4)10 TX patients, B; Group 5)10 normals A; Group 6)7 normals, B. Antibodies were determined for each PS type before, and 1, 3, 12 and 24 months after vaccination. At 1 month: a)the two vaccines produced comparable geometric mean titers (GMT) for 7/12 PS types in normals, 2/14 in NS patients, and 2/14 in TX patients. b)Vaccine B produced higher GMT's for 4/12 PS types in normals and for 11/14 in NS patients. c)Vaccine A produced a greater GMT for 12/14,types in TX patients. The seroconversion rates were similar within paired groups. By 24 months the GMT was5 the pre-vaccine level for 9/12 types in Group 1, 7/12 Group 2, 11/12 Group 3, 6/12 Group 4, 6/12 Group 5, and 3/12 Group 6. The GMT was greater than the assumed protective level of 300 ng antibody N/ml for 4/12 types in Group 1, 5/12 Group 2, 4/12 Group 3, 4/12 Group 4, 5/12 Group 5, and 10/12 Group 6 at 24 months. 25ug of PS provided a similar immune response to that induced by the currently employed 50ug dose. Waning antibody titers suggest that longitudinal assessment of protection is essential and the possible need forbooster doses remains to be determined.
